PREVIOUS
✖
Hydroxyurea Formulation
June 11 , 2024
166 days
260
0
- ICMR has invited Expressions of Interest (EoI) from eligible organisations for the “joint development and commercialisation” of low dose or the paediatric oral formulation of hydroxyurea to treat sickle cell disease in India.
- India has the highest prevalence of sickle cell disease in South Asia, and over 20 million sickle cell affected individuals reside in the country.
- Most pharmaceutical companies in India market 500 mg capsules or 200 mg tablets of hydroxyurea.
- This is the biggest challenge in treatment for effective use in the case of paediatric patients.
Leave a Reply
Your Comment is awaiting moderation.